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Abstract 
The fourth edition of the International Autologous and Allogeneic Cell Therapy for Solid 
Tumors (ATST) meeting was held in Venice, Italy, between March 31 and April 1, 2011. 
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The fourth edition of the International Autolo-
gous and Allogeneic Cell Therapy for Solid Tumors 
(ATST)  meeting  was  held  in  Venice,  Italy,  between 
March 31 and April 1, 2011. The ATST meeting was 
initially organized as a venue for learning the latest 
information  related  to  the  use  of  allogeneic  trans-
plantation for treating in solid tumors. As new im-
munological  and  targeted  therapy  approaches  have 
been  developed,  the  meeting  has  evolved  to  cover 
topics related to the use of novel  cellular and anti-
body-based  approaches  for  treating  advanced  solid 
tumors. 
More  than  20  world-renowned  experts  in  the 
field  of  cellular  and  antibody-based  tumor  immu-
no-biology  and  autologous/allogeneic  transplanta-
tion presented their latest data and discussed novel 
methods of potentiating immunity against cancer. The 
meeting was divided into multiple sessions address-
ing  novel  monoclonal  antibody,  immunotoxin,  ra-
dio-immunoconjugates,  and  vaccine  therapies  for 
cancer as well as novel methods to augment NK-cell 
and  T-cell-based  antitumor  immunity.  The  meeting 
also included sessions that updated the results of au-
tologous and allogeneic transplants for solid tumors, 
as well as methods to enhance graft-vs-tumor effects 
utilizing  tumor  antigen-specific  T-cells,  alloreactive 
NK  cells,  and  post-transplant  tumor  vaccine  ap-
proaches. 
This  special  issue  of  the  Journal  of  Cancer  in-
cludes a summary of each speaker’s presentation from 
the ATST meeting. 
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We hope that you enjoy this special issue of the 
Journal of Cancer. 
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